Novartis (NVS) has made a takeover offer for Avidity Biosciences (RNA), which has a market value of $4.3B, The Financial Times’ Oliver Barnes, James Fontanella-Khan and Hannah Kuchler report. Avidity, which has three medicines in clinical trials that treat different forms of muscular dystrophy, is working with advisers to assess its options, people familiar with the matter say.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Trump Weekly: President says raising tariffs on India ‘substantially’
- Trump says separate tariff announcements coming for semi chips, pharmaceuticals
- Private Markets: Scale rival Surge AI in talks for funding at $25B value
- Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
- Novartis announces FDA approval of label update for Leqvio